Axtria Thought Leadership

Executive insights and perspectives on the Life Sciences industry


Coronavirus Pandemic Effects On Incentive Compensation

White Paper

Coronavirus Pandemic Effects On Incentive Compensation

This paper focuses on coronavirus pandemic effects on IC for pharma companies in the short-term, medium-term, and long-term, while also providing prescriptive actions for sales exe ...

Pharma Incentive Compensation

White paper

Should Pharmaceutical Incentive Compensation Plans Cap At-Risk Sales Rep Compensation?

This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? ...

Patient-Centric Commercial Strategy

White Paper

Designing A Patient-Centric Commercial Strategy

This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...

Coronavirus Pandemic US Pharmaceutical Industry

White Paper

How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry?

The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmac ...

Corona Virus White Paper

White Paper

Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?

Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...

One Important Lesson From Biogen’s Surprise Announcement On Hopes For An Alzheimer’s Drug: A Commentary

White Paper

One Important Lesson From Biogen’s Surprise Announcement On Hopes For An Alzheimer’s Drug

This white paper lays out the reasons for these changes and action steps executives must make to shift from the current volume-based to value/outcomes-based commercial model design ...

Importation of Drugs

White Paper

Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary

This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

White Paper

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...

US Recession Pharma Analytics

White Paper

How Will The Next Great Recession Affect The US Pharma Industry?

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...

Start typing and press Enter to search